Vertex Pharmaceuticals Inc.
VRTX NMS
Pharmaceuticals
Boston, MA
Pharmaceuticals
Boston, MA
| 2017 IW US 500 Rank | 409 |
| 2016 IW US 500 Rank | 517 |
| Executive 1 | Jeffrey Leiden, Chairman; President |
| Executive 2 | Michael Parini, Executive Vice President; Chief Legal Officer |
| 2016 Revenue (US$ Millions) | $1,702 |
| Revenue Growth (%) | 64.89% |
| 2015 Revenue (US$ Millions) | $1,032 |
| Net Income (US$ Millions) | ($112) |
| Common Shares Outstanding (Millions) | 248.3 |
| Earnings Per Share (US$) | ($0.46) |
| Price to Earnings Ratio | N/A |
| Total Equity (US$ Millions) | $1,157 |
| Return on Equity (%) | -11.92% |
| Long Term Debt (US$ Millions) | $521 |
| Debt to Equity Ratio (%) | 0.45% |
| Market Capitalization (US$ Millions) | $18,292 |
| Total Assets (US$ Millions) | $2,897 |
| Current Assets (US$ Millions) | $1,832 |
| Inventories (US$ Millions) | $78 |
| Current Liabilities (US$ Millions) | $793 |
| Cost Of Goods Sold (US$ Millions) | $207 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 3.07 |